BioSpace News Archive

YS Biopharma Co., Ltd. announced that it received an extension of 180 calendar days from The Nasdaq Stock Market LLC to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market, following the expiration of the initial 180 calendar days period to regain compliance on April 22, 2024.

BioCare, a leading specialty pharmaceutical distribution partner comprised of BioCareSD and LogiCare3PL, announced the appointment of James Frary as Chief Executive Officer and Michael Kody as Chief Operating Officer.

Octapharma USA , Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older with von Willebrand disease (VWD).

INOVIO today announced that management will participate in the following investor conferences during the month of May.

Cognito Therapeutics announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May 5-8 in Atlanta, GA.

Stoke Therapeutics, Inc. today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer.

Cerevance today announced that company management will participate in the following investor conferences: Wells Fargo Virtual Private Biotech Symposium, May 6, 2024.

Silence Therapeutics plc today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.

AIM ImmunoTech Inc. announced that it has taken an essential step forward in testing the combination of AIM’s Ampligen® and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® in the treatment of late-stage pancreatic cancer.

Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th anniversary with the company.